Current myasthenia gravis therapies can exacerbate comorbidities or create other complications, said James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.
Current myasthenia gravis therapies can create other complications, said James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, former chief of the Neuromuscular Disorders Division, and former James F. Howard Distinguished Professor of Neuromuscular Disease.
Transcript
Can comorbidities in myasthenia gravis be worsened by current therapies such as prednisone, for example?
Yes. I mean, with prednisone, we worry about the development of diabetes, of hypertension, osteopenia and osteoporosis—thinning of the bones, if you will—to say nothing of the mood changes that people experience when they take this drug. Other drugs have the potential to impact the liver, for instance. Others have potential impact on the ability to form blood cells. Not every patient experiences them, and some patients are successfully treated with very minimal side effects. But in the whole, in the majority, these happen to such a degree that we don't like them and we need to find better.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More